HRP20220096T1 - Inhibitori lizin specifične demetilaze-1 - Google Patents

Inhibitori lizin specifične demetilaze-1 Download PDF

Info

Publication number
HRP20220096T1
HRP20220096T1 HRP20220096TT HRP20220096T HRP20220096T1 HR P20220096 T1 HRP20220096 T1 HR P20220096T1 HR P20220096T T HRP20220096T T HR P20220096TT HR P20220096 T HRP20220096 T HR P20220096T HR P20220096 T1 HRP20220096 T1 HR P20220096T1
Authority
HR
Croatia
Prior art keywords
methyl
fluoro
oxo
dihydro
benzonitrile
Prior art date
Application number
HRP20220096TT
Other languages
English (en)
Croatian (hr)
Inventor
Young K. Chen
Toufike Kanouni
Stephen W. Kaldor
Jeffrey Alan Stafford
James Marvin Veal
Original Assignee
Celgene Quanticel Research, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research, Inc. filed Critical Celgene Quanticel Research, Inc.
Publication of HRP20220096T1 publication Critical patent/HRP20220096T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
HRP20220096TT 2014-05-01 2015-04-30 Inhibitori lizin specifične demetilaze-1 HRP20220096T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987354P 2014-05-01 2014-05-01
EP15785884.6A EP3137169B1 (en) 2014-05-01 2015-04-30 Inhibitors of lysine specific demethylase-1
PCT/US2015/028635 WO2015168466A1 (en) 2014-05-01 2015-04-30 Inhibitors of lysine specific demethylase-1

Publications (1)

Publication Number Publication Date
HRP20220096T1 true HRP20220096T1 (hr) 2022-04-15

Family

ID=54354743

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220096TT HRP20220096T1 (hr) 2014-05-01 2015-04-30 Inhibitori lizin specifične demetilaze-1

Country Status (32)

Country Link
US (9) US9255097B2 (OSRAM)
EP (1) EP3137169B1 (OSRAM)
JP (1) JP6493890B2 (OSRAM)
KR (1) KR102400920B1 (OSRAM)
CN (1) CN106659914B (OSRAM)
AR (1) AR100251A1 (OSRAM)
AU (1) AU2015253040B2 (OSRAM)
BR (1) BR112016025248B1 (OSRAM)
CA (1) CA2947283C (OSRAM)
CL (1) CL2016002736A1 (OSRAM)
CY (1) CY1124959T1 (OSRAM)
DK (1) DK3137169T3 (OSRAM)
EA (1) EA036672B8 (OSRAM)
ES (1) ES2903423T3 (OSRAM)
HR (1) HRP20220096T1 (OSRAM)
HU (1) HUE057895T2 (OSRAM)
IL (1) IL248505B (OSRAM)
LT (1) LT3137169T (OSRAM)
MX (1) MX373373B (OSRAM)
NI (1) NI201600165A (OSRAM)
PE (1) PE20161438A1 (OSRAM)
PH (1) PH12016502179A1 (OSRAM)
PL (1) PL3137169T3 (OSRAM)
PT (1) PT3137169T (OSRAM)
RS (1) RS62874B1 (OSRAM)
SA (2) SA516380201B1 (OSRAM)
SG (1) SG11201609033TA (OSRAM)
SI (1) SI3137169T1 (OSRAM)
SM (1) SMT202200066T1 (OSRAM)
TW (1) TWI676620B (OSRAM)
WO (1) WO2015168466A1 (OSRAM)
ZA (1) ZA201607613B (OSRAM)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
SI3137169T1 (sl) * 2014-05-01 2022-04-29 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
LT3160956T (lt) * 2014-06-27 2020-09-10 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
MX395534B (es) * 2014-07-03 2025-03-25 Celgene Quanticel Res Inc Inhibidores de demetilasa-1 especifica de lisina.
CA2987876A1 (en) 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
US10308660B2 (en) 2015-06-19 2019-06-04 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
WO2016203404A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3310774B1 (en) 2015-06-19 2020-04-29 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
PT3371152T (pt) * 2015-11-05 2021-02-01 Celgene Quanticel Res Inc Composições compreendendo um inibidor de lisina específica desmetilase-1 com um anel de pirimidina e sua utilização no tratamento do cancro
US10059668B2 (en) 2015-11-05 2018-08-28 Mirati Therapeutics, Inc. LSD1 inhibitors
PL3381896T3 (pl) * 2015-11-27 2023-05-08 Taiho Pharmaceutical Co., Ltd. Związek bifenylowy lub jego sól
SG11201805645QA (en) 2015-12-29 2018-07-30 Mirati Therapeutics Inc Lsd1 inhibitors
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
US11034991B2 (en) 2016-03-16 2021-06-15 Oryzon Genomics S.A. Methods to determine KDM1A target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
RU2744988C2 (ru) 2016-06-14 2021-03-17 Новартис Аг Соединения и композиции для подавления активности shp2
MX381059B (es) 2016-08-10 2025-04-01 Celgene Quanticel Res Inc Tratamiento de tumores y linfomas no de hodgkin sólidos, reincididos y/o refractarios.
WO2018059549A1 (en) * 2016-09-30 2018-04-05 Novartis Ag Immune effector cell therapies with enhanced efficacy
EP3535414A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
ES2964956T3 (es) 2017-01-10 2024-04-10 Novartis Ag Combinación farmacéutica que comprende un inhibidor de ALK y un inhibidor de SHP2
ES2991090T3 (es) 2017-03-30 2024-12-02 Univ Freiburg Albert Ludwigs Inhibidores de KDM4
CA3065077C (en) 2017-05-26 2022-09-20 Taiho Pharmaceutical Co., Ltd. Novel biphenyl compound or salt thereof
MA50467A (fr) 2017-05-26 2020-09-02 Taiho Pharmaceutical Co Ltd Potentialisateur d'effet antitumoral utilisant un nouveau composé biphényle
US12435128B2 (en) 2017-05-31 2025-10-07 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
LT3661510T (lt) 2017-08-03 2025-01-27 Oryzon Genomics, S.A. Elgesio pakitimų gydymo būdai
CN112368272B (zh) * 2018-03-21 2023-04-21 苏州浦合医药科技有限公司 Shp2抑制剂及其用途
CN109668987A (zh) * 2019-02-27 2019-04-23 浙江华贝药业有限责任公司 一种3-氨基哌啶二盐酸盐对映异构体测定分析方法
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
CN120837494A (zh) 2019-03-20 2025-10-28 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
MX2021015447A (es) 2019-06-13 2022-04-06 Celgene Corp Métodos de tratamiento del cáncer dirigidos a tumores fríos.
US20220249528A1 (en) 2019-06-20 2022-08-11 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
WO2021063821A1 (en) * 2019-10-01 2021-04-08 Bayer Aktiengesellschaft Pyrimidinedione derivatives
BR112022008020A2 (pt) 2019-11-13 2022-07-12 Taiho Pharmaceutical Co Ltd Métodos de tratamento de doenças e distúrbios relacionados a lsd1 com inibidores de lsd1
JP2023516745A (ja) * 2020-03-06 2023-04-20 セルジーン・クオンティセル・リサーチ・インコーポレイテッド 小細胞肺癌および／または扁平上皮非小細胞肺癌の処置方法
CN116056707A (zh) 2020-06-05 2023-05-02 赛尔基因昆蒂赛尔研究公司 治疗前列腺癌的方法
EP4306520A4 (en) * 2021-03-11 2025-05-07 Medshine Discovery Inc. THIOPHENE COMPOUND AND ITS USE
CN117062813A (zh) * 2021-03-24 2023-11-14 四川汇宇制药股份有限公司 一种多环化合物及其应用
KR20230167102A (ko) 2021-04-08 2023-12-07 오리존 지노믹스 에스.에이. 골수성 암 치료를 위한 lsd1 억제제의 조합물
JP2025516648A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いるｎｆ１変異腫瘍の治療法
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
KR20250110929A (ko) 2022-12-02 2025-07-21 뉴모라 테라퓨틱스, 인코포레이티드 신경학적 장애를 치료하는 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
CN1312807A (zh) * 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
EP1397142A4 (en) * 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
MXPA05005477A (es) * 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
WO2008070908A1 (en) * 2006-12-11 2008-06-19 Bionomics Limited Chemical compounds and processes
AU2009275957A1 (en) * 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
US9365539B2 (en) * 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
PH12013501871A1 (en) 2011-03-25 2019-06-03 Glaxosmithkline Ip No 2 Ltd Cyclopropylamines as lsd1 inhibitors
WO2013175789A1 (ja) 2012-05-24 2013-11-28 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
EP2970285B1 (en) 2013-03-11 2019-04-17 AbbVie Inc. Fused tetracyclic bromodomain inhibitors
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
RS63733B1 (sr) 2013-10-18 2022-12-30 Celgene Quanticel Research Inc Inhibitori bromodomena
JP6430512B2 (ja) * 2013-12-11 2018-11-28 セルジーン クオンティセル リサーチ，インク． リジン特異的デメチラーゼ−１の阻害剤
SI3137169T1 (sl) 2014-05-01 2022-04-29 Celgene Quanticel Research, Inc. Inhibitorji lizin specifične demetilaze-1
US20160022684A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
US20190055235A1 (en) 2014-12-17 2019-02-21 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
PT3371152T (pt) * 2015-11-05 2021-02-01 Celgene Quanticel Res Inc Composições compreendendo um inibidor de lisina específica desmetilase-1 com um anel de pirimidina e sua utilização no tratamento do cancro

Also Published As

Publication number Publication date
EP3137169A1 (en) 2017-03-08
EA201692079A1 (ru) 2017-04-28
CA2947283C (en) 2023-01-24
CN106659914A (zh) 2017-05-10
KR20160144506A (ko) 2016-12-16
SA519410025B1 (ar) 2022-06-01
AU2015253040A1 (en) 2016-11-24
CY1124959T1 (el) 2023-01-05
SMT202200066T1 (it) 2022-03-21
US20170114024A1 (en) 2017-04-27
TW201623254A (zh) 2016-07-01
ES2903423T3 (es) 2022-04-01
IL248505A0 (en) 2016-12-29
US20160152595A1 (en) 2016-06-02
CN106659914B (zh) 2020-06-19
US20220153706A1 (en) 2022-05-19
NI201600165A (es) 2017-03-13
US10654810B2 (en) 2020-05-19
MX2016014253A (es) 2017-02-08
ZA201607613B (en) 2017-11-29
EA036672B1 (ru) 2020-12-07
SA516380201B1 (ar) 2019-11-20
US11084793B2 (en) 2021-08-10
US20160130247A1 (en) 2016-05-12
US20170349555A1 (en) 2017-12-07
US20150315187A1 (en) 2015-11-05
JP2017514830A (ja) 2017-06-08
EP3137169A4 (en) 2018-01-10
US10207999B2 (en) 2019-02-19
US9771329B2 (en) 2017-09-26
US9573930B2 (en) 2017-02-21
CL2016002736A1 (es) 2017-06-23
IL248505B (en) 2021-01-31
JP6493890B2 (ja) 2019-04-03
LT3137169T (lt) 2022-04-11
PT3137169T (pt) 2022-01-25
CA2947283A1 (en) 2015-11-05
DK3137169T3 (da) 2022-02-14
PL3137169T3 (pl) 2022-02-28
WO2015168466A1 (en) 2015-11-05
AR100251A1 (es) 2016-09-21
BR112016025248B1 (pt) 2022-12-13
AU2015253040B2 (en) 2020-04-09
SI3137169T1 (sl) 2022-04-29
US9776974B2 (en) 2017-10-03
AU2015253040A8 (en) 2017-06-15
PH12016502179A1 (en) 2017-02-13
HUE057895T2 (hu) 2022-06-28
US11987560B2 (en) 2024-05-21
BR112016025248A2 (pt) 2018-06-19
SG11201609033TA (en) 2016-11-29
TWI676620B (zh) 2019-11-11
MX373373B (es) 2020-05-12
PE20161438A1 (es) 2017-01-18
US20170349556A1 (en) 2017-12-07
US20200231549A1 (en) 2020-07-23
WO2015168466A8 (en) 2016-11-24
NZ725914A (en) 2023-09-29
US9255097B2 (en) 2016-02-09
RS62874B1 (sr) 2022-02-28
US10023543B2 (en) 2018-07-17
EP3137169B1 (en) 2021-11-10
KR102400920B1 (ko) 2022-05-20
US20180325900A1 (en) 2018-11-15
EA036672B8 (ru) 2021-01-13

Similar Documents

Publication Publication Date Title
HRP20220096T1 (hr) Inhibitori lizin specifične demetilaze-1
HRP20180382T1 (hr) Inhibitori protein kinaze
HRP20210482T1 (hr) Inhibitori serinske/treoninske kinaze
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
HRP20180546T1 (hr) Supstituirani benzilindazoli za uporabu kao inhibitori bub1 kinaze za liječenje hiperproliferativnih bolesti
JP2016519156A5 (OSRAM)
RU2015154987A (ru) Гетероциклические производные
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2016519096A5 (OSRAM)
JP2018516254A5 (OSRAM)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
HRP20230595T1 (hr) Inhibitori lizina specifične demetilaze-1
JP2016530299A5 (OSRAM)
JP2015500332A5 (OSRAM)
JP2013527173A5 (OSRAM)
JP2017500364A5 (OSRAM)
HRP20200098T1 (hr) Spirociklični spojevi kao inhibitori triptofan hidroksilaze
JP2015508828A5 (OSRAM)
RU2018112237A (ru) Новые бициклические соединения в качестве дуальных ингибиторов atx/ca
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
JP2014528446A5 (OSRAM)
JP2019537571A5 (OSRAM)
RU2015137615A (ru) Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4
RU2015143191A (ru) Дигидропирролопиридиновые ингибиторы бромодоменов
HRP20201469T1 (hr) Derivati tetrahidroizokinolina